Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PP110 is a Peritech Pharma topical fixed-dose anti-hemorrhoidal product formulated as a gel and medicated wipes. It combines pramoxine 1% for local anesthetic and antipruritic activity with phenylephrine 0.25% for alpha-1 adrenergic vasoconstrictor activity, delivered in a volatile film-forming formulation intended to leave a protective film and prolong contact of the active ingredients with anorectal tissue. PP110 was evaluated once daily in a randomized open-label Phase 2/3 study for grade 2-3 bleeding hemorrhoids, in which the gel outperformed Preparation-H Maximum Strength Cream for reductions in bleeding, pain, and itching. ([europepmc.org](https://europepmc.org/articles/PMC4506449))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PP110.